British drugmaker Indivior PLC secured a temporary order on Friday to prevent Alvogen Pine Brook LLC from launching its generic buprenorphine and naloxone sublingual film in the U.S.. The drug in question is an opioid addiction treatment that dissolves in the mouth.

A U.S. court quit an injunction against the Suboxone generic that was developed by Dr Reddy’s Laboratories Ltd. The company intends to launch its generic as litigation and a patent infringement appeal surrounding the product are ongoing.

The order is to remain in place until February 7 until a preliminary injunction hearing will take place.

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!